TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients.

ABSTRACT: There is strong evidence that both adoptive T cell transfer and T cell checkpoint blockade can lead to regression of human melanoma. However, little data are available on the effect of these cancer therapies on the tumor-reactive T cell compartment. To address this issue we have profiled therapy-induced T cell reactivity against a panel of 145 melanoma-associated CD8(+) T cell epitopes. Using this approach, we demonstrate that individual tumor-infiltrating lymphocyte cell products from melanoma patients contain unique patterns of reactivity against shared melanoma-associated antigens, and that the combined magnitude of these responses is surprisingly low. Importantly, TIL therapy increases the breadth of the tumor-reactive T cell compartment in vivo, and T cell reactivity observed post-the

SUBMITTER: Kvistborg P 

PROVIDER: S-EPMC3382882 | biostudies-literature | 2012 Jul

REPOSITORIES: biostudies-literature